유바이오로직스

206650KOSDAQ의약품 제조업

61.8 / 100

Reference Date: 2026-04-13

Financial Score23.0 / 40

News Sentiment18.8 / 25

Momentum8.0 / 20

Disclosure12.0 / 15

AI Analysis: ROE significantly exceeds the industry average but PBR raises overvaluation concerns. Declined 9.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

YuBioLogics, established in 2010, is a biotech company specializing in vaccine development and supply, as well as CRMO services. It supplies cholera vaccines to UNICEF, achieving sales of 65.4 billion KRW in 2023, with continued growth driven by increasing global cholera outbreaks. The company aims to expand its product line to include typhoid and meningitis vaccines, targeting global market leadership.

Number of Employees

397people

Average Salary

60.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

11.81Industry Average 14.805.0Point

In line with industry avg

PBR

2.79Industry Average 1.040.0Point

2.7x industry avg (risky)

ROE

26.85Industry Average 4.427.0Point

6.1x industry avg (excellent)

Debt Ratio

13.20Industry Average 11.982.0Point

Higher than industry avg (caution)

Trend 2023~20259.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲46.9% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲211.3% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 9.7% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 2Negative 0Average Sentiment Score 75

Neutral
"제2 팬데믹 막아라"... 치명률 75% 니파바이러스 대비 '백신 라...
정부가 치명률 75%의 니파바이러스 팬데믹에 대비하여 100일 이내 백신 공급을 목표로 '백신 라이브러리' 구축에 나섰습니다.
Neutral
美-이란 전쟁 유탄 맞은 도내 상장기업
미국-이란 전쟁으로 인한 국제유가 상승 여파로 코스피가 하락하며 강원 상장기업 주가도 영향을 받았습니다.

Detailed Momentum

52-week position5.0Point

52w mid range (43%)

Current 13,310Won52-week high 16,20052-week low 11,060

1-month return1.0Point

1m -9.39% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

11 totalPositive 1Neutral 10Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-07
Neutral주식등의대량보유상황보고서(일반)2026-04-07
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-03
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-03-27
Neutral정기주주총회결과2026-03-26